Thomas Kim on Transforming Psychiatric Treatment with Epivario
What we're trying to do is eliminate that intensity by preventing the constant reconsolidation, as the clinical terminology goes, of that traumatic event.
What if there was a way to tackle psychiatric disorders at their root? Thomas Kim, CEO of Epivario, believes his company is on the brink of doing just that. In this episode of 'Mental Health News Radio', Kim opens up about Epivario's groundbreaking approach to mental health treatment. Founded by epigeneticists from the University of Pennsylvania, Epivario is pioneering a drug that targets the ACSS2 gene, aiming to disrupt the formation of negative memories.
This could be a game-changer for conditions like PTSD, Alzheimer's, and even addiction. Kim explains how this innovative drug works by reducing the intensity of fear responses to traumatic events, potentially enhancing the effectiveness of psychotherapy and lowering dropout rates. He also addresses common misconceptions surrounding mental health and mental illness, shedding light on the complexities of these conditions.
For those intrigued by the intersection of science and mental health, this episode offers a fascinating glimpse into the future of psychiatric treatment. Kim doesn't shy away from discussing the challenges Epivario faces as an early-stage company, including funding and navigating social media landscapes. Yet, his optimism about the potential impact of their work is infectious. Listeners will gain a deeper understanding of how cutting-edge science is being harnessed to offer new hope for those struggling with memory-related psychiatric disorders.
If you're curious about the future of mental health treatment and the innovative solutions on the horizon, this episode is a must-listen.